ArticleTranslational cancer research2017
The role of novel immunotherapies in non-Hodgkin lymphoma.
Article in Translational cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Analysis of the clinical characteristics and prognostic factors of multicenter childhood Burkitt leukemia.Annals of hematology · 2025Article
- Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematology.Frontiers in immunology · 2025Review
- Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers.Experimental hematology & oncology · 2024Review
- Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies.Nature communications · 2024Article
- Metabolic Biomarkers in B-Cell Lymphomas for Early Diagnosis and Prediction, as Well as Their Influence on Prognosis and Treatment.Diagnostics (Basel, Switzerland) · 2022Review
- Integrating plant molecular farming and materials research for next-generation vaccines.Nature reviews. Materials · 2022Review
- Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms.Frontiers in immunology · 2022Review
- Histamine in cancer immunology and immunotherapy. Current status and new perspectives.Pharmacology research & perspectives · 2021Review
- Immunotherapy-Related Imaging Findings in Patients with Gynecological Malignancies: What Radiologists Need to Know.Korean journal of radiology · 2021Review
- A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.Frontiers in immunology · 2021Review
- Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in East Asia.Cancer research and treatment · 2020Article
- Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.Translational cancer research · 2019Review
- Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow.Molecular therapy oncolytics · 2019Review
- T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.Haematologica · 2019Article
- Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas.Frontiers in oncology · 2019Review
- Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma.Current clinical pharmacology · 2018Article
- Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies.Frontiers in immunology · 2018Review
- Microenvironment Cell Contribution to Lymphoma Immunity.Frontiers in oncology · 2018Review
- Targeted cellular immunotherapy for T cell malignancies.Nature medicine · 2017Article
- Radiotherapy for Non-Hodgkin Lymphomas.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Immunotherapy is an evolving modality in the treatment of non-Hodgkin lymphoma. Vaccinations with patient-specific tumor-derived antigens have been developed to strengthen immune response to tumor. The success of rituximab, a monoclonal antibody for CD20 on malignant B-cells, fueled further immunotherapy research. The power of the immune system to fight hematologic malignancies is seen in allogeneic stem cell transplant, where donor T cells attack residual malignant cells in the recipient. Now, three innovative therapeutic immunotherapy classes (I) adoptive cellular therapy; (II) immune-checkpoint inhibitors; and (III) novel antibody therapies show promising results in non-Hodgkin lymphoma. Genetically engineered T cells, CAR T cells, obtained remissions in lymphomas refractory to conventional chemotherapy. Immune-checkpoint inhibitors, such as nivolumab and pembrolizumab revolutionized the treatment of many solid tumors, and unprecedented results are now reported in relapsed/refractory lymphoma. Building on the success of rituximab, additional therapeutic monoclonal antibodies were developed for lymphoma treatment. Antibodies have recently been further engineered with multiple binding sites to directly engage both tumor and T cells. There are exciting early clinical trial results for the first bispecific T-cell engager (BiTE), blinatumomab, as well as promising ongoing studies for dual antibody molecules, Dual-Affinity Re-Targeting (DART) proteins. This review highlights these three immunotherapy classes for relapsed/refractory non-Hodgkin lymphomas and discusses the mechanism of action, clinical efficacy, and toxicities of each.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.